IPILIMUMAB and PYREXIA

Overview

PYREXIA is the #6 most commonly reported adverse reaction for IPILIMUMAB, manufactured by E.R. Squibb & Sons, L.L.C.. There are 1,996 FDA adverse event reports linking IPILIMUMAB to PYREXIA. This represents approximately 3.1% of all 65,125 adverse event reports for this drug.

Patients taking IPILIMUMAB who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

PYREXIA is moderately reported among IPILIMUMAB users, representing a notable but not dominant share of adverse events.

Other Side Effects of IPILIMUMAB

In addition to pyrexia, the following adverse reactions have been reported for IPILIMUMAB:

• DEATH — 4,177 reports
• MALIGNANT NEOPLASM PROGRESSION — 3,667 reports
• DIARRHOEA — 3,053 reports
• OFF LABEL USE — 2,351 reports
• COLITIS — 2,270 reports
• RASH — 1,768 reports
• FATIGUE — 1,658 reports
• NAUSEA — 1,358 reports
• INTENTIONAL PRODUCT USE ISSUE — 1,349 reports
• DECREASED APPETITE — 1,087 reports

Other Drugs Associated with PYREXIA

The following drugs have also been linked to pyrexia in FDA adverse event reports:

Does IPILIMUMAB cause PYREXIA?

PYREXIA has been reported as an adverse event in 1,996 FDA reports for IPILIMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is PYREXIA with IPILIMUMAB?

PYREXIA accounts for approximately 3.1% of all adverse event reports for IPILIMUMAB, making it a notable side effect.

What should I do if I experience PYREXIA while taking IPILIMUMAB?

If you experience pyrexia while taking IPILIMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages